Syrosingopine, a dual MCT1/4 inhibitor and old antihypertensive drug with good CNS penetration, showed dose-dependent anti-tumor effects in vitro on U87MG and LN229 glioma cell lines:

Increased cytotoxicity

Enhanced apoptosis

Reduced migration/invasion

Clinical Relevance:

MCT1/4 may serve as diagnostic immunohistochemical markers.

Syrosingopine may represent a promising adjunctive therapy for GBM ¹⁾